Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 6, 2026, 2:11 PM ET
RBC Capital lifts Sarepta price target to $18, maintains Sector Perform rating
Nasdaq: $SRPTMarketed Duchenne therapiesQ3 2026 results · guidance range raised at the low endPMO conversion reviewLiver safety and early RNA risk
SRPT Stock Hub: Sarepta Therapeutics News, ELEVIDYS and FDA Dates
On November 5 Sarepta reported Q3 2026 net product revenue of $323.8 million ($240.3 million PMO, $83.5 million ELEVIDYS), a GAAP operating loss of $9.0 million and $998.7 million of cash, cash equivalents, restricted cash and investments at September 30, and raised the low end of its 2026 product-revenue guidance to $1.25–1.3 billion. ELEVIDYS safety, the February FDA review of two marketed exon-skipping therapies and siRNA multiple-ascending-dose data expected in Q4 2026 remain separate tests. The shares closed at $17.82 on November 6, 2026, up 1.42% from $17.57 a day earlier.
Research Library
The complete SRPT research report
Research report · Edition of November 6, 2026 · Includes the third-quarter 2026 results and the updated 2026 guidance
Next company-guided clinical window
Q4 2026 · SRP-1003 (DM1) and SRP-1001 (FSHD) multiple-ascending-dose data
The November 5 release expects multiple-ascending-dose data from both siRNA programs in the fourth quarter of 2026 and says Sarepta is preparing for potential Phase 3 development, including manufacturing of clinical supply. This is a guided window, not a fixed date. Sarepta was also scheduled to present at two investor conferences on November 9, 2026. Q3 2026 results release.
Completed on November 5, 2026: Q3 results released after the Nasdaq close and discussed on a conference call at 4:30 p.m. ET. Net product revenue was $323.8 million and the low end of 2026 product-revenue guidance was raised by $50 million to $1.25 billion. Q3 Form 10-Q.
Separate regulatory event: February 28, 2027 is the target action date for conversion of AMONDYS 45 and VYONDYS 53 from accelerated to traditional approval. They are already approved drugs; acceptance does not guarantee conversion. FDA-acceptance announcement.
November 5, 2026: Sarepta will not restart enrollment in the Phase 3 ENVISION trial
Important clinical-program decision disclosed November 5. Sarepta said it will close enrollment permanently in the global Phase 3 ENVISION trial of ELEVIDYS in non-ambulatory and late-ambulatory Duchenne muscular dystrophy after a clinical hold lasting more than a year. The trial enrolled 90 participants at sites in 14 countries, including 64 non-ambulatory and 26 late-ambulatory participants. Sarepta plans to analyze the blinded data already collected in Part 1. Closing enrollment is a program decision only: the non-ambulatory indication is not approved, and the Part 1 data remain blinded.
Why the protocol could not simply resume: The company said any restart would require a materially different preventive immunosuppression regimen in the non-ambulatory population—blinded oral sirolimus in addition to corticosteroids—and combining treatment approaches within the original design could compromise interpretation. This is a shift away from ENVISION as the route to an expanded non-ambulatory indication, not an FDA authorization to treat that group.
Next development path: Sarepta continues enrolling non-ambulatory patients in ENDEAVOR Cohort 8, studying whether prophylactic sirolimus plus corticosteroids around ELEVIDYS infusion can mitigate acute liver injury. The company plans FDA discussions in Q1 2027, informed by Cohort 8 safety data. A possible restart or label expansion would depend on evidence and regulatory decisions; the current clinical hold should not be interpreted as lifted.
Participants and evidence: ELEVIDYS recipients in ENVISION may move to long-term EXPEDITION follow-up; participants who received placebo might be eligible for crossover only if study findings, Data Monitoring Committee review and regulatory authorization permit. Sarepta also cited early ENDURE Phase 4 liver-safety monitoring findings without a new safety signal, and two-year motor-function comparisons in older ambulatory children. These findings involve different populations and study designs and must not be assumed to establish benefit in non-ambulatory patients.
Other regulatory milestones: FDA actions on the supplemental NDAs for AMONDYS 45 and VYONDYS 53 remain expected at the end of February 2027 and are distinct from ELEVIDYS safety and ENVISION. Sarepta official Duchenne community letter, November 5, 2026 · Sarepta Q3 2026 release.
SRPT stock: dated key data
Reference close
$17.82
November 6, 2026 Nasdaq regular close; +1.42% versus $17.57 on November 5.
Common shares
107.236M
107,235,848 at November 2, 2026 (Q3 Form 10-Q cover).
Unrestricted cash + investments
$987.6M
September 30, 2026: $472.8M cash and equivalents + $514.8M investments.
Total liquidity measure
$998.7M
September 30, 2026; includes $11.1M of non-current restricted cash and investments.
Q3 net product revenue
$323.8M
Quarter ended September 30, 2026: PMO $240.3M, ELEVIDYS $83.5M; $370.0M a year earlier.
2026 product-revenue outlook
$1.25–1.3B
Management guidance as of November 5 (low end raised from $1.2B); not reported full-year results.
Convertible-note principal
$1.052B
September 30: $158.6M 2027 notes + $893.4M 2030 notes.
Q3 anti-dilutive equivalents
29.1M shares
16.0M convertibles + 13.1M equity plans excluded from Q3 diluted EPS; not issued common shares.
Sources: Q3 Form 10-Q, November 5 results and outlook, Nasdaq market data. Outstanding shares and potential shares use different definitions and dates.
The Q3 10-Q states that the $39.0M patent settlement was paid within ten days of September 23. During the first nine months Sarepta drew and repaid $425.0M under its $600M revolver, which had no amounts outstanding at September 30; borrowing capacity is not cash already held.
SRPT today: an existing franchise with unresolved evidence and funding tests
Sarepta has marketed Duchenne therapies, but ELEVIDYS carries a boxed warning for acute serious liver injury and acute liver failure. Its U.S. indication is limited to eligible ambulatory patients aged four and older with a confirmed DMD mutation. FDA indication and safety information.
AMONDYS 45 and VYONDYS 53 are being reviewed for conversion to traditional approval after ESSENCE missed its prespecified primary endpoint. A favorable review is a conditional outcome, not established by filing acceptance. June 30 acceptance · Regulatory update.
The September WMS analysis in ages 8–12 compared treated patients with external controls, not a randomized group. October SRP-1003 findings were preclinical; they are not proof of human functional benefit. Clinical evidence, product revenue and financing must be evaluated separately. WMS data · October preclinical announcement.
Q3 2026 results, released November 5, showed total revenue of $381.4 million against $399.4 million a year earlier and net product revenue of $323.8 million against $370.0 million: PMO revenue was $240.3 million and ELEVIDYS revenue $83.5 million, down from $131.5 million as the updated label limited treatment to ambulatory patients. The GAAP operating loss narrowed to $9.0 million and the net loss to $28.5 million; cost of sales included a $62.0 million take-or-pay charge for Catalent manufacturing obligations. Nine-month operating cash flow was a positive $54.4 million. Sarepta raised the low end of its 2026 product-revenue guidance to $1.25–1.3 billion and narrowed combined non-GAAP R&D and SG&A guidance to $800–825 million; these are company forecasts, not results. Q3 results release · Q3 Form 10-Q.
Main risk: Commercial safety restrictions, confirmatory-evidence uncertainty, early clinical risk and contractual cash obligations can reinforce one another even while products remain on the market.
Constructive case
Commercial demand stabilizes, the PMO review resolves favorably and repeat-dose siRNA studies show consistent biological and functional evidence. Those conditional improvements could strengthen franchise durability and the development path; Q3 brought positive nine-month operating cash flow and a higher low end of revenue guidance.
Cautious case
Weaker product economics or an adverse regulatory outcome increases reliance on early programs whose clinical benefit remains unproven. Development and contractual costs could then tighten funding and increase dilution risk; ELEVIDYS revenue fell to $83.5 million in Q3 from $131.5 million a year earlier.
SRPT stock news: six selected updates
Nov 10, 2026
MIS51ON high-dose eteplirsen study marked completed on ClinicalTrials.gov
The ClinicalTrials.gov record for NCT03992430 was updated to COMPLETED on 2026-11-10. The Phase 3 study compares safety and efficacy of high doses of eteplirsen in participants with Duchenne muscular dystrophy (DMD), with Sarepta Therapeutics, Inc. as lead sponsor. Enrollment was 160, and the completion date is 2026-09-07.
Nov 6, 2026
RBC Capital lifts Sarepta price target to $18, maintains Sector Perform rating
RBC Capital raised its price target on Sarepta Therapeutics to $18 from $17. The bank kept its Sector Perform rating. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 5, 2026
Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta reported net product revenues of approximately $323.8 million for the third quarter 2026, including approximately $240.3 million of PMO and $83.5 million of ELEVIDYS. Total revenues were $381.4 million, with a GAAP operating loss of $(9.0) million and non-GAAP operating income of $22.9 million. The company raised the low end of its 2026 total net product revenue guidance by $50.0 million, to a range of $1.25 billion to $1.3 billion, and ended the quarter with approximately $998.7 million in cash, cash equivalents, restricted cash and investments.
Oct 26, 2026
November investor conferences scheduled
Management will participate in two November 9 investor conferences. The Guggenheim fireside chat is scheduled for 3:00 p.m. Eastern; a conference appearance is not a promised clinical result.
Oct 22, 2026
Q3 results scheduled for November 5
After-close results will be followed by a 4:30 p.m. Eastern call. Updated revenue and cash information remain forthcoming.
Oct 14, 2026
SRP-1003 preclinical data presented
Laboratory and animal findings describe nuclear and cytoplasmic DMPK knockdown, RNA-foci reduction and splice correction. They are not patient clinical outcomes. Sarepta said Phase 1/2 results were planned later in 2026.
SRPT stock catalysts: dated milestones
- November 5, 2026 · Q3 financial resultsCompleted
Net product revenue $323.8M; 2026 product-revenue guidance $1.25–1.3B; released after the Nasdaq close and discussed on a conference call at 4:30 p.m. ET. Results release.
- November 9, 2026 · Investor conferencesScheduled event, November 9
Presentation dates do not guarantee new data.
- Q4 2026 · SRP-1003 and SRP-1001 multiple-ascending-dose dataCompany-guided window
The Q3 release expects DM1 and FSHD multiple-ascending-dose data in the fourth quarter; no precise date is given. Q3 release.
- Q1 2027 · ENDEAVOR cohort 8 safetyCompany-guided window
Safety evidence under enhanced immunosuppression is separate from a label expansion.
- February 28, 2027 · AMONDYS 45 / VYONDYS 53 reviewFDA target action date
Conversion applications for already approved therapies, with outcome uncertain.
- September 15, 2027 · 2027 convertible notesContractual maturity
Principal $158.6M at September 30, 2026; future refinancing or conversion is not assumed.
ELEVIDYS and RNA evidence: the comparator and endpoint matter
A positive external-control comparison cannot be described as a randomized trial. Likewise, micro-dystrophin expression in very young children is a biomarker finding, not a functional-benefit measure, and it does not extend the current label. The FDA’s ambulatory indication and liver warning remain the relevant approved terms. WMS release · FDA.
SRP-1003’s October findings are preclinical. Repeated-dose patient data, target response, functional outcomes and safety are distinct steps. The ESSENCE primary-endpoint miss remains relevant to the separate PMO conversion review.
SRPT cash, debt and licensed-program obligations
September 30 unrestricted cash, cash equivalents and investments were $987.6M, with a broader $998.7M measure including restricted assets. Convertible principal is approximately $1.052B, distinct from accounting carrying value. The Q3 10-Q lists material cash requirements over the next 12 months, including repayment of the $158.6M 2027 notes due September 2027, a second $50.0M annual license fee payable to Arrowhead in February 2027 and $22.1M still payable to Catalent under the take-or-pay charge, and states that cash, operating inflows and revolver availability are sufficient for at least the next twelve months. Potential convertible and equity-plan shares are not current issued shares. Q3 filing.
Arrowhead licensing includes annual fees, contingent milestones and royalties. A $200M DM1 milestone was paid during H1 2026; the maximum potential milestone total includes achieved milestones and must not be represented as all still payable. Under the September 23 patent settlement Sarepta paid $39.0M within ten days of effectiveness, according to the Q3 10-Q. Licensing disclosures · Settlement filing.
The securities case’s district-court dismissal is under appeal. It is a separate matter from the patent settlement. Q3 10-Q litigation note.
Merlintrader Health Score · SRPT
3.30out of 5
Weighted editorial assessment of November 6, 2026, after the Q3 results; balance-sheet score raised from 3.5 to 4: 4×30% + 3×30% + 3×20% + 3.5×10% + 2.5×10% = 3.30/5. Financial baseline September 30 and market reference November 6. It describes robustness, not valuation, a price target or an investment recommendation. Reviewed November 9, 2026: scores unchanged.
SRPT red flags
- ELEVIDYS has a boxed liver-safety warning and a limited ambulatory U.S. indication.
- ESSENCE missed its prespecified primary endpoint; PMO application acceptance does not guarantee traditional approval.
- External controls, expression biomarkers and preclinical experiments are not interchangeable with randomized functional benefit.
- Convertible principal, licensing payments, settlement obligations and equity awards constrain the headline liquidity reading.
- Q3 cost of sales included a $62.0M take-or-pay charge for Catalent manufacturing obligations, of which $22.1M remained unpaid at September 30.
- The securities-action dismissal is under appeal; historical balances are not current cash.
SRPT Stock FAQ: Sarepta Therapeutics Questions Answered
What is the next catalyst for SRPT stock?
Sarepta reported Q3 2026 results on November 5, 2026. Its release expects multiple-ascending-dose data from SRP-1003 in DM1 and SRP-1001 in FSHD in the fourth quarter of 2026, and the company was scheduled at two investor conferences on November 9. The next FDA target action date is February 28, 2027, for conversion applications involving AMONDYS 45 and VYONDYS 53. Those drugs already have accelerated approvals; the review outcome remains uncertain. Q3 2026 results and guided data window. PMO conversion review schedule.
Is Sarepta’s ELEVIDYS approved for all Duchenne patients?
No. As of November 2, 2026, the FDA’s ELEVIDYS indication covers ambulatory patients aged four and older with a confirmed DMD mutation. It does not cover every Duchenne patient. The label has important eligibility restrictions and a boxed warning for acute serious liver injury and acute liver failure, including fatal outcomes. FDA indication and limitations. FDA boxed-warning and indication action.
How much cash and investments does Sarepta have?
Sarepta’s September 30, 2026, liquidity measure was $998.7 million, including restricted assets. It comprised $472.8 million of cash and equivalents, $514.8 million of investments and $11.1 million of non-current restricted cash and investments. The $600 million revolver had no amounts outstanding at that date after $425.0 million was drawn and repaid during the first nine months; available borrowing is separate from cash held. September liquidity and credit-facility disclosures.
How many shares does Sarepta have outstanding?
Sarepta had 107,235,848 common shares outstanding on November 2, 2026. Its Q3 accounts excluded approximately 29.1 million potential common shares from diluted earnings per share because they were anti-dilutive for that quarter. These convertible-debt and equity-plan equivalents were potential shares, distinct from issued common shares and later grants. Quarterly EPS exclusions and common shares.
When did Sarepta last report earnings?
Sarepta reported Q3 2026 financial results on November 5, 2026, after the Nasdaq market closed, and discussed on a conference call at 4:30 p.m. ET. The webcast replay is archived on the investor-relations site for one year. As of November 5, the date of the full-year 2026 report had not been announced. Q3 2026 results release. Q3 Form 10-Q.
What does Sarepta Therapeutics do?
Sarepta develops genetic medicines for rare diseases, with a marketed Duchenne muscular dystrophy franchise and research across muscle, nervous-system and cardiac diseases. Its products include the gene therapy ELEVIDYS and exon-skipping medicines EXONDYS 51, AMONDYS 45 and VYONDYS 53. Its 2026 disclosures distinguish these marketed therapies from investigational pipeline programs. Company overview. Marketed exon-skipping portfolio. Business and pipeline overview.
What is Sarepta’s February 28, 2027, FDA review about?
Sarepta’s June 30, 2026, announcement identifies February 28, 2027, as the FDA target action date for applications to convert AMONDYS 45 and VYONDYS 53 from accelerated to traditional approval. The ESSENCE confirmatory trial missed its prespecified primary endpoint. Sarepta also cites post hoc analyses and real-world evidence, which are exploratory and do not replace a met primary endpoint; the FDA target action date for the conversion decision is February 28, 2027. Applications, ESSENCE and supporting analyses.
What did Sarepta’s September ELEVIDYS data show?
Sarepta’s September 30, 2026 WMS release compares treated children aged eight to twelve with matched external controls. A separate younger-child analysis reports micro-dystrophin expression, rather than established functional benefit. Those observations neither turn the external-control comparison into a randomized result nor expand the FDA label to children under four. WMS analysis designs and younger-child findings. Current FDA indication.
Primary sources
- November 5, 2026 · Sarepta Q3 2026 results and updated guidance (Form 8-K, Exhibit 99.1)
- November 5, 2026 · SEC Q3 Form 10-Q
- SEC Q2 Form 10-Q
- Sarepta Q2 results and outlook
- FDA ELEVIDYS indication and safety
- Sarepta FDA acceptance of PMO applications
- Sarepta ESSENCE regulatory update
- Sarepta October 26 conferences
- Sarepta October 22 results schedule
- Sarepta October 14 preclinical announcement
- Securities action: Q3 10-Q litigation note
- Sarepta September 30 WMS release
- Sarepta September 30 grants
- SEC September 23 settlement filing
- Nasdaq market reference
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $SRPT or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
